From Revolution Medicines, more strong data on KRAS drug and a glimpse of a ‘novel class’ beyond it Biotech tested daraxonrasib earlier in pancreatic cancer and has preclinical data on a RAS modulator

https://www.statnews.com/2026/04/21/aacr-2026-pancreatic-cancer-revolution-medicines-future/ By Angus ChenApril 21, 2026 Cancer Reporter